- Home
- VPG vs RIGL Comparison
VPG vs RIGL Comparison
Compare VPG & RIGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | VPG | RIGL |
|---|---|---|
| Founded | 2009 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electrical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 715.7M | 628.4M |
| IPO Year | 2010 | 2000 |
Fundamental Metrics
Financial Performance| Metric | VPG | RIGL |
|---|---|---|
| Price | $43.44 | $28.25 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 5 |
| Target Price | ★ $53.50 | $43.20 |
| AVG Volume (30 Days) | 283.4K | ★ 332.3K |
| Earning Date | 01-01-0001 | 05-22-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 1867.68 |
| EPS | 0.40 | ★ 19.48 |
| Revenue | ★ $307,202,000.00 | $294,282,000.00 |
| Revenue This Year | $7.21 | $66.81 |
| Revenue Next Year | $6.92 | N/A |
| P/E Ratio | $108.25 | ★ $1.48 |
| Revenue Growth | 0.22 | ★ 64.15 |
| 52 Week Low | $18.57 | $15.50 |
| 52 Week High | $56.25 | $52.24 |
Technical Indicators
Market Signals| Indicator | VPG | RIGL |
|---|---|---|
| Relative Strength Index (RSI) | 41.96 | 26.00 |
| Support Level | $37.61 | $27.23 |
| Resistance Level | $49.72 | $31.26 |
| Average True Range (ATR) | 2.78 | 1.71 |
| MACD | -0.68 | -0.56 |
| Stochastic Oscillator | 25.95 | 6.52 |
Price Performance
Historical ComparisonAbout VPG Vishay Precision Group Inc.
Vishay Precision Group Inc manufactures and markets sensors, and sensor-based measurement systems, as well as specialty resistors and strain gages based on proprietary technology. The company provides precision products and solutions, many of which are designed-in by customers, specializing in the growing markets of stress, force, weight, pressure, and current measurements. The company reports in three product segments: Sensors segment, Weighing Solutions segment, and Measurement Systems segment. It has a business presence in the United States and other countries. It generates the maximum of its revenue from the United States.
About RIGL Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.